OrbiMed Advisors led the completion of a $200 million debt facility for Harmony Biosciences, a firm that develops treatment options for people living with rare diseases.
The . . .
Continue Reading With a Free Trial
Unlock this article instantly, along with the rest of our premium content, newsletters and mandate charts.
Already a subscriber? Log in.